Literature DB >> 8230015

Cancer in association with polymyalgia rheumatica and temporal arteritis.

H J Haga1, G E Eide, J Brun, A Johansen, F Langmark.   

Abstract

In our prospective controlled study, a total of 185 patients with polymyalgia rheumatica (PMR) and temporal arteritis (TA) diagnosed during 1978-83 and their 925 matched controls were cross checked with the data files at the Cancer Registry of Norway at the end of 1987. Malignancy was registered in 27 patients (14.6%) and 131 controls (14.2%) between 1953 and the end of 1987. Malignancy was registered in 16 (24.6%) of the patients with biopsy demonstrating arteritis temporalis. The hazard rate for developing malignancy after diagnosis for the whole patient population was not significantly different from the controls. The hazard rate for developing malignancy in patients with positive biopsy, however, was 2.35 times higher than in the controls (p = 0.036) and 4.40 times higher than the rest of the patient population (p = 0.007) (Cox proportional hazards model). The general long interval between diagnosis of PMR and/or TA and registration of malignancy (mean 6.5 years) is not consistent with a paraneoplastic mechanism.

Entities:  

Mesh:

Year:  1993        PMID: 8230015

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 2.  [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Authors:  F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

3.  Association between rheumatic diseases and cancer: results from a clinical practice cohort study.

Authors:  Mattia Bellan; Enrico Boggio; Daniele Sola; Antonello Gibbin; Alessandro Gualerzi; Serena Favretto; Giulia Guaschino; Ramona Bonometti; Roberta Pedrazzoli; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Intern Emerg Med       Date:  2017-02-08       Impact factor: 3.397

4.  Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.

Authors:  J Askling; L Klareskog; H Hjalgrim; E Baecklund; M Björkholm; A Ekbom
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

5.  Malignancy risk in vasculitis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Shreyasee Amin
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

6.  Polymyalgia Rheumatica and its Association with Cancer.

Authors:  Emily C Pfeifer; Cynthia S Crowson; Brittny T Major; Eric L Matteson
Journal:  Rheumatology (Sunnyvale)       Date:  2015-05-07

7.  Cancer preceding giant cell arteritis: a case-control study.

Authors:  Tanaz A Kermani; Valentin S Schäfer; Cynthia S Crowson; Gene G Hunder; Steven R Ytterberg; Eric L Matteson; Sherine E Gabriel; Kenneth J Warrington
Journal:  Arthritis Rheum       Date:  2010-06

8.  The process from symptom onset to rheumatology clinic in polymyalgia rheumatica.

Authors:  Ediz Dalkılıç; Ayşe Nur Tufan; Emre Hafızoğlu; Merve Hafızoğlu; Fatih Tufan; Ferhat Oksuz; Yavuz Pehlivan; Mustafa Yurtkuran
Journal:  Rheumatol Int       Date:  2014-05-11       Impact factor: 2.631

9.  Autoimmunity and the risk of myeloproliferative neoplasms.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2010-01-06       Impact factor: 9.941

Review 10.  Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Authors:  Dario Camellino; Andrea Giusti; Giuseppe Girasole; Gerolamo Bianchi; Christian Dejaco
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.